Janux Therapeutics Closes $125 Million Series B Financing to Advance Next Generation T Cell Engager Immunotherapies into Clinical Trials

• Proceeds support advancement of the company’s pipeline of TRACTr drug candidates into clinical trials
• Funding round supported by top-tier crossover investor syndicate, including RA Capital Management, BVF Partners L.P., EcoR1 Capital, Janus Henderson Investors, Logos Capital, OrbiMed, Samsara BioCapital, Surveyor Capital, and other investors

SAN DIEGO, April 20, 2021-- Janux Therapeutics today announced the closing of a $125 million Series B financing led by RA Capital Management and joined by new investors BVF Partners L.P., EcoR1 Capital, Hartford HealthCare …